Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

作者：Reardon D A^*; Dresemann G; Taillibert S; Campone M; van den Bent M; Clement P; Blomquist E; Gordower L; Schultz H; Raizer J; Hau P; Easaw J; Gil M; Tonn J; Gijtenbeek A; Schlegel U; Bergstrom P; Green S; Weir A; Nikolova Z

来源：British Journal of Cancer, 2009, 101(12): 1995-2004.

DOI：10.1038/sj.bjc.6605411

• glioblastoma
• imatinib mesylate
• platelet-derived growth factor
• c-KIT

BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs).
METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS).
RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%).
CONCLUSION: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity. British Journal of Cancer (2009) 101, 1995-2004. doi: 10.1038/sj.bjc.6605411 www.bjcancer.

• 出版日期2009-12-8
• 单位西北大学